| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer
|
Mirtsching, Barry
|
|
2011
|
11 |
2 |
p. 121-128
8 p.
|
article
|
| 2 |
Editorial Board/Masthead
|
|
|
2011
|
11 |
2 |
p. iv-
1 p.
|
article
|
| 3 |
Interval Between Breast-Conserving Surgery and Start of Radiation Therapy in Early-Stage Breast Cancer is Not Predictive of Local Recurrence: A Single-Institution Experience
|
Barbieri, Viviana
|
|
2011
|
11 |
2 |
p. 114-120
7 p.
|
article
|
| 4 |
Kaposiform Hemangioendothelioma of the Breast in an Adult Female
|
Kim, Min Geun
|
|
2011
|
11 |
2 |
p. 135-137
3 p.
|
article
|
| 5 |
Management and Outcome of HER2-Positive Early Breast Cancer Treated With or Without Trastuzumab in the Adjuvant Trastuzumab Era
|
Palmieri, Carlo
|
|
2011
|
11 |
2 |
p. 93-102
10 p.
|
article
|
| 6 |
Peripheral Neuropathy with Microtubule-Targeting Agents: Occurrence and Management Approach
|
Carlson, Karen
|
|
2011
|
11 |
2 |
p. 73-81
9 p.
|
article
|
| 7 |
Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial
|
Hamberg, Paul
|
|
2011
|
11 |
2 |
p. 103-113
11 p.
|
article
|
| 8 |
Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
|
Robert, Nicholas J.
|
|
2011
|
11 |
2 |
p. 82-92
11 p.
|
article
|
| 9 |
Survivin As a Predictive Biomarker of Complete Pathologic Response to Neoadjuvant Chemotherapy in Patients With Stage II and Stage III Breast Cancer
|
Petrarca, Cristiane Rios
|
|
2011
|
11 |
2 |
p. 129-134
6 p.
|
article
|
| 10 |
Table of Contents
|
|
|
2011
|
11 |
2 |
p. v-vi
nvt p.
|
article
|
Journal description